Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · February 23, 2024

Cardiovascular and Mortality Outcomes With GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs in Individuals With NAFLD and Type 2 Diabetes



Additional Info

Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Diabetologia 2024 Mar 01;67(3)483-493, A Krishnan, CV Schneider, Y Hadi, D Mukherjee, B AlShehri, SA Alqahtani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading